先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

交易中 06-16 13:19:51

9.820

-0.290

-2.87%

最高10.180	最低9.810	成交量128.90万
今开10.180	昨收10.110	日振幅3.66%
总市值252.18亿	流通市值252.18亿	总股本25.68亿
成交额1,273万	换手率0.05%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":9.82,"timestamp":1781587176667,"preClose":10.11,"halted":0,"volume":1289000,"delay":0,"changeRate":-0.028684470820969254,"floatShares":2568000000,"shares":2568000000,"eps":0.625527175317809,"marketStatus":"交易中","change":-0.29,"latestTime":"06-16 13:19:51","open":10.18,"high":10.18,"low":9.81,"amount":12729235,"amplitude":0.036597,"askPrice":9.84,"askSize":43000,"bidPrice":9.82,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.625527175317809,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781597400000},"marketStatusCode":2,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":10.11,"dividendRate":0.021188,"openAndCloseTimeList":[[1781573400000,1781582400000],[1781586000000,1781596800000]],"volumeRatio":0.282096,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0737861772.HKD","01951","01177","09996","LU0320764599.SGD","02268","06078","02273","06821","HK0000306685.HKD","LU0051755006.USD","06990","LU1960683339.HKD","01276","01093","LU0502904849.HKD","LU1242518857.USD","LU0348827113.USD","IE00B0JY6N72.USD","LU3063872942.SGD","03692","06996","01952","02269","02096","LU0140636845.USD","09966","09926","BK1576","LU0819121731.USD","LU1226287875.USD","HK0000320264.USD","01530","BK1191","00013","LU0181495838.USD","LU0456827905.SGD","LU2097828631.EUR","SG9999002562.SGD","LU1688375341.USD","IE00BZ08YR35.GBP","06160","LU1880383366.USD","03759","LU2399975544.HKD","01801","01548","02162","02596","03329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642295887","title":"先声药业(02096)将于7月13日派发末期股息每股0.18元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642295887","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642295887?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:11","pubTimestamp":1781269907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，该公司将于2026年7月13日派发末期股息每股0.18元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VIG","BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293703","title":"先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642293703?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:02","pubTimestamp":1781269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体，通过解除肿瘤细胞免疫抑制和抗血管生成，发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中，SIM0689在低剂量即展现出优异的抗肿瘤疗效，整体药效显著优于同类型分子，提示其在多种实体瘤中有广泛的应用前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1169590202.USD","02096","PD","BK4023","BK1583","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134012338","title":"先声药业宣派末期股息每股0.18元人民币，派息日7月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=1134012338","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134012338?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:01","pubTimestamp":1781269312,"startTime":"0","endTime":"0","summary":"先声药业于2026年6月12日发布更新公告，明确截至2025年12月31日止年度的末期普通股息分派方案。公司宣派末期股息每股0.18元人民币，并以港元作为预设派发货币，按中国人民银行公布的汇率1人民币兑1.1496港元折算，折合每股派息0.2069港元。根据公告，此次派息的除净日定为2026年6月17日。为符合获取股息分派资格，股东须在2026年6月18日下午4时30分前递交股份过户文件。股息最终派发日为2026年7月13日。本次股息不涉及代扣代缴所得税。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业宣派末期股息每股0.18元人民币，派息日7月13日","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105597894","title":"先声药业SIM0689获国家药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1105597894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105597894?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:01","pubTimestamp":1781269283,"startTime":"0","endTime":"0","summary":"先声药业宣布，其研发的创新药物SIM0689已正式获得中国国家药品监督管理局的临床试验批准。此项批准标志着该药物在中国本土的临床开发进程迈出了关键一步，为其后续的临床研究提供了法规基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130542183","title":"先声药业宣派末期股息每股0.18元，7月13日前后派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130542183","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130542183?lang=zh_cn&edition=full","pubTime":"2026-06-12 20:56","pubTimestamp":1781268981,"startTime":"0","endTime":"0","summary":"先声药业在2026年6月12日举行的股东周年大会上，通过决议宣派截至2025年12月31日止年度的末期股息，每股人民币0.18元。股息将以港元派付，按中国人民银行公布的股东周年大会日期前5个营业日人民币兑港元平均汇率中间价换算，折合每股0.2069港元。据此推算，除净日为2026年6月18日。末期股息预计将于2026年7月13日（星期一）或之前，派付予6月24日名列公司股东名册的股东。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业宣派末期股息每股0.18元，7月13日前后派发","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188726205","title":"先声药业携手斯坦福医学院 共研特发性肺纤维化创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1188726205","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188726205?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:00","pubTimestamp":1781247616,"startTime":"0","endTime":"0","summary":"先声药业与斯坦福医学院达成一项研究合作协议，双方将共同致力于开发针对特发性肺纤维化患者的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642108254","title":"港股异动 | 先声药业(02096)午后涨超3% 近日与普祺医药就普美昔替尼凝胶订立独家推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642108254","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642108254?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:39","pubTimestamp":1781069998,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业(02096)午后涨超3%，截至发稿，涨3.03%，报9.87港元，成交额4009.82万港元。消息面上，近日，先声药业发布公告，本集团与北京普祺医药科技股份有限公司(普祺医药)就普美昔替尼凝胶订立独家推广服务协议(该协议)。根据该协议，本集团将获得普美昔替尼凝胶在中国内地、香港及澳门所有皮肤病领域适应症的独家推广权益。目前，普美昔替尼凝胶成人与青少年特应性皮炎(AD)适应症新药上市申请(NDA)已获国家药品监督管理局药品审评中心(CDE)受理。本次合作将进一步强化本集团在自身免疫领域的产品布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02096","BK4585","09939","BK1574","BK4588","BK1515","BK1191","BK1161","BK1583","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103670289","title":"先声药业回购2749.90万股，涉资约3.12亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103670289","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103670289?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:08","pubTimestamp":1780920524,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年6月8日公告，截至当日，公司已完成多笔股份购回，合计回购股份数量约2749.90万股，占回购前已发行股份总数约1.06%。相关股份购回价格范围每股约为10.4901港元至11.8259港元，共计耗资约3.12亿港元。公告显示，本次回购股份分别于2026年1月12日至5月22日期间多次进行，并已于2025年6月8日注销。回购完成后，公司已发行股本由原先的25.95697618亿股变更至25.68198618亿股，库藏股数保持为零。此公告由执行董事及联席公司秘书万玉山签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业回购2749.90万股，涉资约3.12亿港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641328481","title":"先声药业(02096)6月8日注销2749.9万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641328481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641328481?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:56","pubTimestamp":1780919779,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)公布，2026年6月8日注销2749.9万股已回购股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112668284","title":"先声药业5月股份变动月报：股本维持不变，购回股份尚未注销","url":"https://stock-news.laohu8.com/highlight/detail?id=1112668284","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112668284?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:36","pubTimestamp":1780475815,"startTime":"0","endTime":"0","summary":"2026年6月3日，先声药业集团有限公司发布截至2026年5月31日的证券变动月报表。本月公告主要披露公司已发行股本结构、股份买卖及潜在发行安排等内容。根据公告，先声药业当前已发行的普通股股数为2,595,697,618股，较上月底的2,595,697,618股无变化。库存股份数目维持为0股。先声药业于2023年6月15日修订并重列的受限制股份单位计划下，截至5月31日仍有235,201,361股可于日后发行。公司声明将持续遵守香港联交所《上市规则》和适用法律法规的相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640922332","title":"先声药业与普祺医药达成合作；和仁科技终止筹划控制权变更事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2640922332","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640922332?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:02","pubTimestamp":1780444935,"startTime":"0","endTime":"0","summary":"政策动向开展消化介入类医用耗材产品信息集中维护国家组织高值医用耗材联合采购办公室发布《关于开展消化介入类医用耗材产品信息集中维护工作的通知》显示，按照工作安排，将于2026年6月1日起开展消化介入类医用耗材产品信息集中维护工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606033758181427.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033758181427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","300550","BK1583","BK0231","BK1574","BK0146","159938","09939","BK1161","BK1515","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640560569","title":"先声药业(02096)与普祺医药就普美昔替尼凝胶订立独家推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640560569","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640560569?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:38","pubTimestamp":1780313924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年6月1日，本集团与北京普祺医药科技股份有限公司(普祺医药)就普美昔替尼凝胶订立独家推广服务协议(该协议)。根据该协议，本集团将获得普美昔替尼凝胶在中国内地、香港及澳门所有皮肤病领域适应症的独家推广权益。目前，普美昔替尼凝胶成人与青少年特应性皮炎(AD)适应症新药上市申请(NDA)已获国家药品监督管理局药品审评中心(CDE)受理。本次合作将进一步强化本集团在自身免疫领域的产品布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02096","09939","BK1161","BK1191","BK1515","BK1583","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175968868","title":"先声药业取得普米克替尼凝胶在华独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=1175968868","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175968868?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:38","pubTimestamp":1780313922,"startTime":"0","endTime":"0","summary":"先声药业已成功获得创新药物普米克替尼凝胶在中国大陆、香港及澳门地区的独家推广权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137257200","title":"先声药业与Primegenx Therapeutics达成独家推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1137257200","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137257200?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:37","pubTimestamp":1780313852,"startTime":"0","endTime":"0","summary":"先声药业宣布，已与Primegenx Therapeutics签署了一份独家推广服务协议。此举标志着公司在拓展其产品商业化网络方面迈出了新的一步。根据协议，先声药业将获得Primegenx Therapeutics相关产品在中国市场的独家推广权，旨在通过其成熟的销售渠道和市场经验，加速产品的市场渗透与患者可及性。此次合作有望为双方带来新的增长动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638458367","title":"先声药业于5月22日斥资869.63万港元回购82.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638458367","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638458367?lang=zh_cn&edition=full","pubTime":"2026-05-25 07:36","pubTimestamp":1779665760,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　先声药业（02096）发布公告，于2026年5月22日斥资869.63万港元回购82.9万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-25/doc-inhzafpt5228544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140124157","title":"先声药业回购82.9万股股份，耗资约869.63万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140124157","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140124157?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:21","pubTimestamp":1779452512,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年5月22日公告，当日通过香港联交所场内回购普通股82.9万股，占该次回购前已发行股本约0.0319%，最高购回价格为每股10.5804港元，最低购回价格为每股10.4118港元，总金额约869.63万港元。公司已发行股本在本次回购后仍为2,595,697,618股，库藏股数为0。先声药业集团有限公司表示，相关购回事宜已经董事会正式授权，且遵守香港联合交易所有限公司证券上市规则及其他适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业回购82.9万股股份，耗资约869.63万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637117033","title":"先声药业(02096)5月22日斥资869.63万港元回购82.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637117033","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637117033?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:17","pubTimestamp":1779452222,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年5月22日斥资869.63万港元回购82.9万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113615351","title":"先声药业建议派发末期股息每股0.18元，待股东大会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1113615351","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113615351?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:21","pubTimestamp":1779358884,"startTime":"0","endTime":"0","summary":"先声药业(02096)发布股东周年大会通告，建议派发截至2025年12月31日止年度的末期股息每股人民币0.18元，惟须待于2026年6月12日举行的股东周年大会上获股东批准后方可作实。\n为厘定享有末期股息的股东资格，公司将于2026年6月19日至6月24日期间暂停办理股份过户登记手续。股东须于2026年6月18日下午4时30分前，将股份过户表格连同相关股票送交公司香港股份过户登记处，方可获享建议末期股息。派息日期有待后续公布。\n本次股东周年大会将同时审议重选董事、续聘核数师、授出股份发行及购回一般性授权等多项普通决议案，以及修订公司章程的特别决议案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业建议派发末期股息每股0.18元，待股东大会批准","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188284241","title":"先声药业拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1188284241","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188284241?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:16","pubTimestamp":1779358605,"startTime":"0","endTime":"0","summary":"先声药业近日在公告中披露，董事会已提请股东大会授予股份购回授权，拟按不超过公司已发行股份总数10%的规模进行回购，相关数量可达2,595,697,618股的10%，即最多259,569,761股。根据公告，先声药业在最后实际可行日期前六个月已于联交所累计回购22,485,000股股份，成交价区间介乎每股港币10.94元至11.91元。董事会表示，若获股东正式批准，将于授权有效期内灵活行使股份购回权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":0.0498},{"period":"1month","weight":-0.1116},{"period":"3month","weight":-0.1582},{"period":"6month","weight":-0.1976},{"period":"1year","weight":-0.1658},{"period":"ytd","weight":-0.1554}],"compareEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0397},{"period":"6month","weight":-0.0246},{"period":"1year","weight":0.0398},{"period":"ytd","weight":-0.0307}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.093182},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070781},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014071},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003689},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105963},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032911},{"month":7,"riseRate":0.2,"avgChangeRate":-0.0521},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05132},{"month":9,"riseRate":0.4,"avgChangeRate":-0.0324},{"month":10,"riseRate":0.8,"avgChangeRate":0.108781},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044275},{"month":12,"riseRate":0.5,"avgChangeRate":0.000552}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}